$MDLN

Medline reported Q2 sales up 11.6% to $7.685B and net income down 58.3% to $139M, citing $336M fire-related losses tied to its Tracy, California distribution center. For 1H 2026, sales rose 11.1% to $15.037B. Medline said it signed over $650M in new customer business and is adding distribution centers, automation, and workers, including California capacity expansion to about 5M sq ft by mid-2027.

Medline (MDLN) Q2 2026 call said adjusted EBITDA rose 13% YoY to $1.1B, with higher costs partly offset by a $243M IEEPA tariff refund benefit. Q2 net sales grew 12% to $7.7B. Company raised fiscal 2026 organic sales outlook, but moderated adjusted EBITDA outlook citing Middle East conflict, Tracy warehouse fire, investments, quality remediation, and retail softness.

Medline Inc. (NASDAQ: MDLN) received an FDA warning letter dated May 28, 2026 citing significant Current Good Manufacturing Practice violations, including inadequate investigation of batch discrepancies and microbial contamination, and poor cleaning practices, according to the FDA and Reuters. After the FDA news, MDLN shares fell over 7%. On Aug. 5, the stock dropped over 12% after Q2 results and lowered full-year adjusted EBITDA guidance.

Kaplan Fox said the FDA issued a May 28, 2026 warning letter to Medline (NASDAQ: MDLN) citing significant Current Good Manufacturing Practice violations, including failures to investigate unexplained batch discrepancies and microbial contamination incidents. Reuters reported it was the second FDA action in two months. Medline shares fell $2.56, or 7.16%, to $33.19 on June 2, 2026.

Medline said regulatory guidance followed its corrective actions for surgical convenience kits whose components were affected by a Becton Dickinson recall. The alert cites BD lot 4032183 ChloraPrep Clear 1 mL and lot 4073005 FREPP Clear 1.5 mL applicators, with compromised sterile seals and possible Aspergillus contamination. Medline reported no severe injuries or deaths as of Aug 3. MDLN shares were $35.71, up 0.61%.

Kaplan Fox said the FDA issued a May 28, 2026 warning letter to Medline (NASDAQ: MDLN) citing significant Current Good Manufacturing Practice violations, including failures to investigate unexplained batch discrepancies and microbial contamination incidents. Reuters reported it was the second FDA action in two months. Medline shares fell $2.56, or 7.16%, to close at $33.19 on June 2, 2026.

GIC Private Ltd sold 590,284 shares of Medline Inc. (MDLN) at $35.58 ($21.00M total) on 2026-08-07.

The FDA issued a warning letter to Medline (NASDAQ:MDLN) dated May 28, 2026 citing significant Current Good Manufacturing Practice violations, including failures to investigate discrepancies and microbial contamination incidents and inadequate cleaning practices, Reuters reported. Medline shares fell over 7% after the news and over 12% on Aug. 5 after Q2 results and lowered full-year adjusted EBITDA guidance.

Medline Inc. (MDLN) disclosed in a Schedule 13G/A that Blackstone-affiliated entities and Stephen A. Schwarzman may be deemed to beneficially own 153,327,675 Class A shares, or 16.5% of the class, as of June 30, 2026. The filing cites 875,111,752 Class A shares outstanding as of May 28, 2026, held via multiple “Mozart” vehicles and related structures.

GIC Private Ltd sold 2,248,612 shares of Medline Inc. (MDLN) at an average of $35.56 ($35.33–$36.48, $79.97M total) across 3 trades over 2026-08-05 to 2026-08-06.